

Alberto M Pereira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2967088/publications.pdf>

Version: 2024-02-01

331
papers

17,159
citations

15001

68
h-index

25230

113
g-index

339
all docs

339
docs citations

339
times ranked

11853
citing authors

#	ARTICLE	IF	CITATIONS
1	Low sclerostin levels after long-term remission of acromegaly. <i>Endocrine</i> , 2022, 75, 228-238.	1.1	2
2	Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly. <i>Pituitary</i> , 2022, 25, 229-237.	1.6	3
3	Impact of patient-reported nasal symptoms on quality of life after endoscopic pituitary surgery: a prospective cohort study. <i>Pituitary</i> , 2022, 25, 308-320.	1.6	4
4	Towards a pituitary apoplexy classification based on clinical presentation and patient journey. <i>Endocrine</i> , 2022, 76, 132-141.	1.1	4
5	ENDO-ERN ON RARE ENDOCRINE CONDITIONS: Endo-ERN in its fifth year: a pinch of care, science, curiosity and new horizons. <i>Endocrine Connections</i> , 2022, 11, .	0.8	1
6	Gene expression changes in the brain of a Cushing's syndrome mouse model. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13124.	1.2	8
7	State of the Art of Patient-reported Outcomes in Acromegaly or GH Deficiency: A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1225-1238.	1.8	9
8	Long-term effects of glucocorticoid excess on the brain. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	1.2	23
9	Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN). <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 178.	1.2	8
10	Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. <i>Pituitary</i> , 2022, 25, 587-601.	1.6	9
11	Clinical and radiographic assessment of peripheral joints in controlled acromegaly. <i>Pituitary</i> , 2022, 25, 622-635.	1.6	5
12	Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 188-200.	1.8	17
13	Improvement in Symptoms and Health-Related Quality of Life in Acromegaly Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 577-587.	1.8	19
14	Pre-operative serum inflammation-based scores in patients with pituitary adenomas. <i>Pituitary</i> , 2021, 24, 334-350.	1.6	21
15	Healthcare utilization and costs among prolactinoma patients: a cross-sectional study and analysis of determinants. <i>Pituitary</i> , 2021, 24, 79-95.	1.6	5
16	Postoperative endocrinological follow-up. , 2021, , 439-446.		0
17	Variants of FOXO3 and RPA3 genes affecting IGF-1 levels alter the risk of development of primary osteoarthritis. <i>European Journal of Endocrinology</i> , 2021, 184, 29-39.	1.9	6
18	Educational and knowledge gaps within the European reference network on rare endocrine conditions. <i>Endocrine Connections</i> , 2021, 10, 37-44.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Introduction to Endo-ERN's scope and mission. <i>Endocrine</i> , 2021, 71, 537-538.	1.1	7
20	Patients with rare endocrine conditions have corresponding views on unmet needs in clinical research. <i>Endocrine</i> , 2021, 71, 561-568.	1.1	4
21	Effects of Long-Term Endogenous Corticosteroid Exposure on Brain Volume and Glial Cells in the AdKO Mouse. <i>Frontiers in Neuroscience</i> , 2021, 15, 604103.	1.4	24
22	Conditioning cortisol in healthy young women – A randomized controlled trial. <i>Psychoneuroendocrinology</i> , 2021, 124, 105081.	1.3	5
23	Central serous chorioretinopathy in active endogenous Cushing's syndrome. <i>Scientific Reports</i> , 2021, 11, 2748.	1.6	10
24	Access to patient oriented information – a baseline Endo-ERN survey among patients with rare endocrine disorders. <i>Endocrine</i> , 2021, 71, 542-548.	1.1	3
25	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa205.	0.1	31
26	CPMS – improving patient care in Europe via virtual case discussions. <i>Endocrine</i> , 2021, 71, 549-554.	1.1	13
27	Outcome Squares Integrating Efficacy and Safety, as Applied to Functioning Pituitary Adenoma Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3300-e3311.	1.8	7
28	European Reference Networks: challenges and opportunities. <i>Journal of Community Genetics</i> , 2021, 12, 217-229.	0.5	21
29	Serum Inflammation-based Scores in Endocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3796-e3819.	1.8	19
30	Adrenal Vein Sampling in a Patient With Primary Hyperaldosteronism and Severe Contrast Allergy. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab122.	0.1	4
31	SALIVARY ALPHA-AMYLASE LEVELS MAY CORRELATE WITH CENTRAL SEROUS CHORIORETINOPATHY ACTIVITY. <i>Retina</i> , 2021, 41, 2479-2484.	1.0	8
32	Clinical Unmet Needs in the Treatment of Adrenal Crisis: Importance of the Patient's Perspective. <i>Frontiers in Endocrinology</i> , 2021, 12, 701365.	1.5	8
33	The PRolaCT studies – a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma. <i>Trials</i> , 2021, 22, 653.	0.7	7
34	Loss of glucocorticoid rhythm induces an osteoporotic phenotype in female mice. <i>Aging Cell</i> , 2021, 20, e13474.	3.0	9
35	Potential associations between immune signaling genes, deactivated microglia, and oligodendrocytes and cortical gray matter loss in patients with long-term remitted Cushing's disease. <i>Psychoneuroendocrinology</i> , 2021, 132, 105334.	1.3	6
36	Postoperative diabetes insipidus: how to define and grade this complication?. <i>Pituitary</i> , 2021, 24, 284-291.	1.6	50

#	ARTICLE	IF	CITATIONS
37	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	5.5	315
38	Hypophysitis: A comprehensive overview. <i>Presse Medicale</i> , 2021, 50, 104076.	0.8	7
39	The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone. <i>BMJ Open</i> , 2021, 11, e054405.	0.8	3
40	Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1020-1029.	1.8	66
41	Early postoperative HPA-axis testing after pituitary tumor surgery: reliability and safety of basal cortisol and CRH test. <i>Endocrine</i> , 2020, 67, 161-171.	1.1	14
42	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e937-e946.	1.8	207
43	Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e32-e41.	1.8	78
44	IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e70-e84.	1.8	22
45	Hair cortisol concentrations in chronic central serous chorioretinopathy. <i>Acta Ophthalmologica</i> , 2020, 98, 390-395.	0.6	5
46	SF-12 or SF-36 in pituitary disease? Toward concise and comprehensive patient-reported outcomes measurements. <i>Endocrine</i> , 2020, 70, 123-133.	1.1	10
47	The EuRECa Project as a Model for Data Access and Governance Policies for Rare Disease Registries That Collect Clinical Outcomes. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8743.	1.2	13
48	Endoscopic Surgery for Pituitary Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 487-503.	1.2	17
49	SUN-070 European Registries for Rare Endocrine Conditions (EuRECa): Results from the Platform for E-reporting of Rare Endocrine Conditions (e-REC). <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
50	Cortical thickness abnormalities in long-term remitted Cushing's disease. <i>Translational Psychiatry</i> , 2020, 10, 293.	2.4	12
51	Multidisciplinary management of acromegaly: A consensus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 667-678.	2.6	183
52	The epidemiology of aggressive pituitary tumors (and its challenges). <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 209-212.	2.6	38
53	Feasibility, safety, and outcomes of a stratified fast-track care trajectory in pituitary surgery. <i>Endocrine</i> , 2020, 69, 175-187.	1.1	18
54	Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study. <i>Pituitary</i> , 2020, 23, 417-429.	1.6	7

#	ARTICLE	IF	CITATIONS
55	Response to Letter to the Editor: "Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3040-e3041.	1.8	4
56	Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN). <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 144.	1.2	15
57	Psychiatric and neurocognitive consequences of endogenous hypercortisolism. <i>Journal of Internal Medicine</i> , 2020, 288, 168-182.	2.7	35
58	Response to Letter to the Editor: "IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2315-e2316.	1.8	0
59	Glucocorticoid Sexual Dimorphism in Metabolism: Dissecting the Role of Sex Hormones. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 357-367.	3.1	32
60	Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 348.	5.5	1
61	Decreased Aerobic Exercise Capacity After Long-Term Remission From Cushing Syndrome: Exploration of Mechanisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1408-e1418.	1.8	6
62	Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1729-1738.	3.1	23
63	⁶⁸ Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 4.	0.6	5
64	Peptide hormone analysis in diagnosis and treatment of Differences of Sex Development: joint position paper of EU COST Action "DSDnet" and European Reference Network on Rare Endocrine Conditions. <i>European Journal of Endocrinology</i> , 2020, 182, P1-P15.	1.9	20
65	An overview of clinical activities in Endo-ERN: the need for alignment of future network criteria. <i>European Journal of Endocrinology</i> , 2020, 183, 141-148.	1.9	9
66	Progression of vertebral fractures in long-term controlled acromegaly: a 9-year follow-up study. <i>European Journal of Endocrinology</i> , 2020, 183, 427-437.	1.9	24
67	Improvement but no normalization of quality of life and cognitive functioning after treatment for Cushing's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5325-5337.	1.8	27
68	Sex Differences in Presentation but Not in Outcome for ACTH-Dependent Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2019, 10, 580.	1.5	13
69	Acromegaly. <i>Nature Reviews Disease Primers</i> , 2019, 5, 20.	18.1	247
70	Healthcare utilization and costs among patients with non-functioning pituitary adenomas. <i>Endocrine</i> , 2019, 64, 330-340.	1.1	9
71	Microscopic versus endoscopic transsphenoidal surgery in the Leiden cohort treated for Cushing's disease: surgical outcome, mortality, and complications. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 64.	1.2	24
72	Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy. <i>Acta Ophthalmologica</i> , 2019, 97, e572-e579.	0.6	18

#	ARTICLE	IF	CITATIONS
73	The partner's perspective of the impact of pituitary disease: Looking beyond the patient. <i>Journal of Health Psychology</i> , 2019, 24, 1687-1697.	1.3	19
74	The current landscape of European registries for rare endocrine conditions. <i>European Journal of Endocrinology</i> , 2019, 180, 89-98.	1.9	25
75	The incidence of adrenal crisis in the postoperative period of HPA axis insufficiency after surgical treatment for Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2019, 181, 201-210.	1.9	14
76	Toward Value Based Health Care in pituitary surgery: application of a comprehensive outcome set in perioperative care. <i>European Journal of Endocrinology</i> , 2019, 181, 375-387.	1.9	19
77	High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. <i>European Journal of Endocrinology</i> , 2019, 181, 461-472.	1.9	53
78	Three percent annually on systemic glucocorticoids: facts, worries and perspectives. <i>European Journal of Endocrinology</i> , 2019, 181, C23-C28.	1.9	6
79	Effects of Glucocorticoids on the Brain. , 2019, , 360-368.		0
80	Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. <i>European Journal of Endocrinology</i> , 2018, 178, 399-409.	1.9	37
81	How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review. <i>Pituitary</i> , 2018, 21, 208-216.	1.6	29
82	How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. <i>Pituitary</i> , 2018, 21, 310-322.	1.6	19
83	Preoperative risk factors for postoperative complications in endoscopic pituitary surgery: a systematic review. <i>Pituitary</i> , 2018, 21, 84-97.	1.6	84
84	Decrease in scale invariance of activity fluctuations with aging and in patients with suprasellar tumors. <i>Chronobiology International</i> , 2018, 35, 368-377.	0.9	5
85	Selective glucocorticoid receptor modulation prevents and reverses non-alcoholic fatty liver disease in male mice. <i>Endocrinology</i> , 2018, 159, 3925-3936.	1.4	27
86	Work disability and its determinants in patients with pituitary tumor-related disease. <i>Pituitary</i> , 2018, 21, 593-604.	1.6	31
87	Endoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a systematic review and meta-analysis. <i>Pituitary</i> , 2018, 21, 524-534.	1.6	71
88	Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis. <i>Pituitary</i> , 2018, 21, 631-641.	1.6	61
89	Cognitive functioning and quality of life in patients with Hashimoto thyroiditis on long-term levothyroxine replacement. <i>Endocrine</i> , 2018, 62, 136-143.	1.1	49
90	Cushing's Syndrome and Hypothalamic-Pituitary-Adrenal Axis Hyperactivity in Chronic Central Serous Chorioretinopathy. <i>Frontiers in Endocrinology</i> , 2018, 9, 39.	1.5	22

#	ARTICLE	IF	CITATIONS
91	Bone material strength index as measured by impact microindentation is altered in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2017, 176, 339-347.	1.9	51
92	The phenotype of SDHB germline mutation carriers: a nationwide study. <i>European Journal of Endocrinology</i> , 2017, 177, 115-125.	1.9	38
93	Enhanced self-efficacy after a self-management programme in pituitary disease: a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2017, 177, 59-72.	1.9	38
94	Acromegalic arthropathy in various stages of the disease: an MRI study. <i>European Journal of Endocrinology</i> , 2017, 176, 779-790.	1.9	18
95	Glucocorticoid Regulation of Neurocognitive and Neuropsychiatric Function. , 2017, , 27-41.		0
96	Corticosteroid use and mortality risk in patients with perforated colonic diverticular disease: a population-based cohort study. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000136.	1.1	14
97	A Patient (46XX) With Congenital Adrenal Hyperplasia and Prostate Cancer: A Case Report. <i>Journal of the Endocrine Society</i> , 2017, 1, 1213-1216.	0.1	7
98	Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters. <i>Frontiers in Endocrinology</i> , 2017, 8, 40.	1.5	63
99	Characteristics and Mortality of Pneumocystis Pneumonia in Patients With Cushing's Syndrome: A Plea for Timely Initiation of Chemoprophylaxis. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx002.	0.4	18
100	Cataplexy in a patient treated for prolactinoma: Case report. <i>Vojnosanitetski Pregled</i> , 2017, 74, 782-785.	0.1	1
101	Primary hypercortisolism and pheochromocytoma next to, but not related to, each other. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015213359.	0.2	0
102	Chronic Central Serous Chorioretinopathy as a Presenting Symptom of Cushing Syndrome. <i>European Journal of Ophthalmology</i> , 2016, 26, 442-448.	0.7	27
103	The Role of the Suprachiasmatic Nucleus in Cardiac Autonomic Control during Sleep. <i>PLoS ONE</i> , 2016, 11, e0152390.	1.1	3
104	DIAGNOSIS OF ENDOCRINE DISEASE: Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2016, 175, R247-R253.	1.9	21
105	Intraoperative Identification of a Normal Pituitary Gland and an Adenoma Using Near-Infrared Fluorescence Imaging and Low-Dose Indocyanine Green. <i>Operative Neurosurgery</i> , 2016, 12, 260-268.	0.4	20
106	Pituitary Hormone Secretion Profiles in IGSF1 Deficiency Syndrome. <i>Neuroendocrinology</i> , 2016, 103, 408-416.	1.2	22
107	IGSF1 Deficiency: Lessons From an Extensive Case Series and Recommendations for Clinical Management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1627-1636.	1.8	68
108	Optimizing Blood Sampling Protocols in Patients With Acromegaly for the Estimation of Growth Hormone Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2675-2682.	1.8	8

#	ARTICLE	IF	CITATIONS
109	Identification of a selective glucocorticoid receptor modulator that prevents both diet-induced obesity and inflammation. <i>British Journal of Pharmacology</i> , 2016, 173, 1793-1804.	2.7	35
110	Vascular Health in Patients in Remission of Cushing's Syndrome Is Comparable With That in BMI-Matched Controls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4142-4150.	1.8	12
111	Quality of life in patients with adrenal insufficiency correlates stronger with hydrocortisone dosage, than with long-term systemic cortisol levels. <i>Psychoneuroendocrinology</i> , 2016, 72, 80-86.	1.3	15
112	Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 569-576.	5.5	151
113	Mild deficits in attentional control in patients with the IGSF1 deficiency syndrome. <i>Clinical Endocrinology</i> , 2016, 84, 896-903.	1.2	20
114	Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. <i>European Journal of Endocrinology</i> , 2016, 174, 651-662.	1.9	40
115	The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary. <i>Pituitary</i> , 2016, 19, 293-302.	1.6	30
116	Effects of discontinuation of growth hormone replacement in adult GH-deficient patients: a cohort study and a systematic review of the literature. <i>European Journal of Endocrinology</i> , 2016, 174, 705-716.	1.9	9
117	Mild cognitive deficits in patients with primary adrenal insufficiency. <i>Psychoneuroendocrinology</i> , 2016, 63, 170-177.	1.3	24
118	Mild cognitive deficits in patients on stable treatment for primary adrenal insufficiency. <i>Psychoneuroendocrinology</i> , 2015, 61, 46.	1.3	2
119	Neuropsychological functioning in acromegaly: towards identification of modifiable factors to improve long-term care after remission. <i>Endocrine</i> , 2015, 50, 523-525.	1.1	2
120	Persistent negative illness perceptions despite long-term biochemical control of acromegaly: novel application of the drawing test. <i>European Journal of Endocrinology</i> , 2015, 172, 583-593.	1.9	21
121	MECHANISMS IN ENDOCRINOLOGY: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. <i>European Journal of Endocrinology</i> , 2015, 173, R1-R14.	1.9	141
122	Increased Hair Cortisol Concentrations and BMI in Patients With Pituitary-Adrenal Disease on Hydrocortisone Replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2456-2462.	1.8	21
123	Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. <i>Pituitary</i> , 2015, 18, 752-776.	1.6	95
124	Resting-State Functional Connectivity in Patients with Long-Term Remission of Cushing's Disease. <i>Neuropsychopharmacology</i> , 2015, 40, 1888-1898.	2.8	44
125	STAT5B mutations in heterozygous state have negative impact on height: another clue in human stature heritability. <i>European Journal of Endocrinology</i> , 2015, 173, 291-296.	1.9	29
126	Total score or subscales in scoring the acromegaly quality of life questionnaire: using novel confirmatory methods to compare scoring options. <i>European Journal of Endocrinology</i> , 2015, 173, 37-42.	1.9	5

#	ARTICLE	IF	CITATIONS
127	MANAGEMENT OF ENDOCRINE DISEASE: Mortality remains increased in Cushing's disease despite biochemical remission: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2015, 172, R143-R149.	1.9	80
128	Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2171-2180.	1.8	304
129	Outcome of complications in acromegaly patients after long-term disease remission. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 499-510.	1.2	4
130	Hypothalamicâ€Pituitaryâ€Adrenal Axis Functioning in Huntington's Disease and its Association with Depressive Symptoms and Suicidality. <i>Journal of Neuroendocrinology</i> , 2015, 27, 234-244.	1.2	32
131	Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. <i>European Journal of Endocrinology</i> , 2015, 173, 269-273.	1.9	23
132	More concerns and stronger beliefs about the necessity of medication in patients with acromegaly are associated with negative illness perceptions and impairment in quality of life. <i>Growth Hormone and IGF Research</i> , 2015, 25, 219-226.	0.5	19
133	Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3288-3296.	1.8	116
134	Altered neural processing of emotional faces in remitted Cushing's disease. <i>Psychoneuroendocrinology</i> , 2015, 59, 134-146.	1.3	40
135	Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL. <i>Pituitary</i> , 2015, 18, 86-100.	1.6	51
136	Response to the Letter by Lindholm, et al. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, L66-L67.	1.8	0
137	High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma. <i>PLoS ONE</i> , 2014, 9, e90602.	1.1	15
138	Determinants of Altered Sleep-Wake Rhythmicity in Patients Treated for Nonfunctioning Pituitary Macroadenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4497-4505.	1.8	23
139	Hormone Secretion by Pituitary Adenomas Is Characterized by Increased Disorderliness and Spikiness but More Regular Pulsing. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3836-3844.	1.8	9
140	Effects of up to 15 years of recombinant human <sc>GH</sc> (rh<sc>GH</sc>) replacement on bone metabolism in adults with Growth Hormone Deficiency (<sc>GHD</sc>): The Leiden Cohort Study. <i>Clinical Endocrinology</i> , 2014, 81, 727-735.	1.2	29
141	Pituitary dysfunction in adult patients after cranial irradiation for head and nasopharyngeal tumours. <i>Radiotherapy and Oncology</i> , 2014, 113, 102-107.	0.3	29
142	A longâ€term followâ€up study of eighteen patients with thyrotrophinâ€secreting pituitary adenomas. <i>Clinical Endocrinology</i> , 2014, 80, 395-402.	1.2	52
143	Patients With Adrenal Insufficiency Hate Their Medication: Concerns and Stronger Beliefs About the Necessity of Hydrocortisone Intake Are Associated With More Negative Illness Perceptions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3668-3676.	1.8	27
144	Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy. <i>European Journal of Endocrinology</i> , 2014, 170, 181-191.	1.9	19

#	ARTICLE	IF	CITATIONS
145	Impact of Adiposity and Fat Distribution on the Dynamics of Adrenocorticotropin and Cortisol Rhythms. <i>Current Obesity Reports</i> , 2014, 3, 387-395.	3.5	9
146	Alterations in diurnal rhythmicity in patients treated for nonfunctioning pituitary macroadenoma: a controlled study and literature review. <i>European Journal of Endocrinology</i> , 2014, 171, 217-228.	1.9	33
147	Abnormal metabolic phenotype in middle-aged GH-deficient adults despite long-term recombinant human GH replacement. <i>European Journal of Endocrinology</i> , 2014, 170, 263-272.	1.9	7
148	Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. <i>Pituitary</i> , 2014, 17, 44-52.	1.6	25
149	Thyrotropin Secretion in Healthy Subjects Is Robust and Independent of Age and Gender, and Only Weakly Dependent on Body Mass Index. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 570-578.	1.8	28
150	Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: cross-sectional study and review of the literature. <i>European Journal of Endocrinology</i> , 2014, 171, 171-182.	1.9	61
151	Relationship between the functional exon 3 deleted growth hormone receptor polymorphism and symptomatic osteoarthritis in women. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 433-436.	0.5	5
152	Copy number variants in patients with short stature. <i>European Journal of Human Genetics</i> , 2014, 22, 602-609.	1.4	60
153	Long-term effects of treatment of pituitary adenomas. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014, 124, 361-371.	1.0	7
154	Widespread reductions of white matter integrity in patients with long-term remission of Cushing's disease. <i>NeuroImage: Clinical</i> , 2014, 4, 659-667.	1.4	76
155	D05 Hypothalamic-pituitary-adrenal Axis Activity in Huntington's Disease And Its Association With Depressive Symptoms And Suicidality. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, A33-A33.	0.9	0
156	Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease. <i>Pituitary</i> , 2013, 16, 536-544.	1.6	26
157	An Activating Mutation in the Kinase Homology Domain of the Natriuretic Peptide Receptor-2 Causes Extremely Tall Stature Without Skeletal Deformities. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1988-E1998.	1.8	78
158	The IGSF1 Deficiency Syndrome: Characteristics of Male and Female Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4942-4952.	1.8	81
159	Loss-of-function mutations in the immunoglobulin superfamily member 1 gene (IGSF1) cause a novel, X-linked syndrome of central hypothyroidism and testicular enlargement. <i>Lancet, The</i> , 2013, 381, S15.	6.3	0
160	Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). <i>Growth Hormone and IGF Research</i> , 2013, 23, 159-164.	0.5	14
161	Multisystem Morbidity and Mortality in Cushing's Syndrome: A Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2277-2284.	1.8	324
162	Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing's disease: a case-control study. <i>European Journal of Endocrinology</i> , 2013, 169, 811-819.	1.9	84

#	ARTICLE	IF	CITATIONS
163	Relationship between left ventricular diastolic function and arterial stiffness in asymptomatic patients with diabetes mellitus. <i>International Journal of Cardiovascular Imaging</i> , 2013, 29, 609-616.	0.7	19
164	Metabolic Profile in Growth Hormone-Deficient (GHD) Adults after Long-Term Recombinant Human Growth Hormone (rhGH) Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 352-361.	1.8	57
165	Progression of Vertebral Fractures Despite Long-Term Biochemical Control of Acromegaly: A Prospective Follow-up Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4808-4815.	1.8	90
166	Therapy of Endocrine disease: Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. <i>European Journal of Endocrinology</i> , 2013, 169, R1-R14.	1.9	74
167	Preoperative Normalization of Cortisol Levels in Cushing's Disease After Medical Treatment: Consequences for Somatostatin and Dopamine Receptor Subtype Expression and In Vitro Response to Somatostatin Analogs and Dopamine Agonists. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, F1880-F1890.	1.8	44
168	Non-invasive assessment of microcirculation by sidestream dark field imaging as a marker of coronary artery disease in diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 123-134.	0.9	26
169	Glucocorticoid excess induces long-lasting changes in body composition in male C57Bl/6J mice only with high-fat diet. <i>Physiological Reports</i> , 2013, 1, e00103.	0.7	12
170	Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice. <i>PLoS ONE</i> , 2013, 8, e63882.	1.1	14
171	Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2012, 166, 27-34.	1.9	62
172	Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. <i>European Journal of Endocrinology</i> , 2012, 167, 235-244.	1.9	46
173	MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects. <i>European Journal of Endocrinology</i> , 2012, 167, 311-326.	1.9	226
174	The Hypercoagulable State in Cushing's Disease Is Associated with Increased Levels of Procoagulant Factors and Impaired Fibrinolysis, But Is Not Reversible after Short-Term Biochemical Remission Induced by Medical Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1303-1310.	1.8	92
175	Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. <i>European Journal of Endocrinology</i> , 2012, 166, 407-413.	1.9	19
176	Genetic Analysis of Short Children with Apparent Growth Hormone Insensitivity. <i>Hormone Research in Paediatrics</i> , 2012, 77, 320-333.	0.8	45
177	The use of an early postoperative CRH test to assess adrenal function after transsphenoidal surgery for pituitary adenomas. <i>Pituitary</i> , 2012, 15, 436-444.	1.6	12
178	Treatment of nonfunctioning pituitary adenomas: What were the contributions of the last 10years? A critical view. <i>Annales D'Endocrinologie</i> , 2012, 73, 111-116.	0.6	20
179	Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. <i>Nature Genetics</i> , 2012, 44, 1375-1381.	9.4	169
180	Drawings Reflect a New Dimension of the Psychological Impact of Long-Term Remission of Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3123-3131.	1.8	32

#	ARTICLE	IF	CITATIONS
181	The effects of high fat diet on the basal activity of the hypothalamus-pituitary-adrenal axis in mice. <i>Journal of Endocrinology</i> , 2012, 214, 191-197.	1.2	48
182	Relationship between insulin-like growth factor-1 and radiographic disease in patients with primary osteoarthritis: a systematic review. <i>Osteoarthritis and Cartilage</i> , 2012, 20, 79-86.	0.6	19
183	Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. <i>Clinical Endocrinology</i> , 2012, 77, 99-105.	1.2	54
184	Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. <i>Pituitary</i> , 2012, 15, 71-83.	1.6	274
185	Cognitive impairment and psychopathology in patients with pituitary diseases. <i>Netherlands Journal of Medicine</i> , 2012, 70, 255-60.	0.6	20
186	Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2011, 18, 264-268.	1.2	17
187	Relationship between vascular stiffness and stress myocardial perfusion imaging in asymptomatic patients with diabetes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2050-2057.	3.3	10
188	Low Incidence of Adrenal Insufficiency after Transsphenoidal Surgery in Patients with Acromegaly: A Long-Term Follow-Up Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1163-E1170.	1.8	17
189	Incidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3525-3532.	1.8	161
190	Patients Previously Treated for Nonfunctioning Pituitary Macroadenomas Have Disturbed Sleep Characteristics, Circadian Movement Rhythm, and Subjective Sleep Quality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1524-1532.	1.8	50
191	Pituitary Dysfunction in Adult Patients after Cranial Radiotherapy: Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2330-2340.	1.8	126
192	Meta-Analysis and Dose-Response Metaregression: Circulating Insulin-Like Growth Factor I (IGF-I) and Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2912-2920.	1.8	131
193	Affected Illness Perceptions and the Association with Impaired Quality of Life in Patients with Long-Term Remission of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3550-3558.	1.8	69
194	Negative illness perceptions are associated with impaired quality of life in patients after long-term remission of Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2011, 165, 527-535.	1.9	77
195	Low prevalence of hypopituitarism after traumatic brain injury: a multicenter study. <i>European Journal of Endocrinology</i> , 2011, 165, 225-231.	1.9	59
196	Effects of High Fat Diet on the Basal Activity of the Hypothalamus-Pituitary-Adrenal Axis in Mice: A Systematic Review. <i>Hormone and Metabolic Research</i> , 2011, 43, 899-906.	0.7	23
197	Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 320-325.	0.5	43
198	Comparison of the cortisol responses to testing with two doses of ACTH in patients with suspected adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2011, 164, 83-87.	1.9	16

#	ARTICLE	IF	CITATIONS
199	GH replacement therapy in elderly GH-deficient patients: a systematic review. <i>European Journal of Endocrinology</i> , 2011, 164, 657-665.	1.9	50
200	The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. <i>European Journal of Endocrinology</i> , 2011, 165, 383-392.	1.9	322
201	Coping Strategies in Patients after Treatment for Functioning or Nonfunctioning Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 964-971.	1.8	67
202	High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. <i>European Journal of Endocrinology</i> , 2011, 164, 475-483.	1.9	125
203	Manifesto for the current understanding and management of traumatic brain injury-induced hypopituitarism. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 541-3.	1.8	17
204	Endocriene tumoren. , 2011, , 513-555.		0
205	The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 1385-1391.	3.1	40
206	Neuropsychiatric Disorders in Cushing's Syndrome. <i>Neuroendocrinology</i> , 2010, 92, 65-70.	1.2	125
207	Abnormal cardiac contractility in long-term exogenous subclinical hyperthyroid patients as demonstrated by two-dimensional echocardiography speckle tracking imaging. <i>European Journal of Endocrinology</i> , 2010, 163, 435-441.	1.9	25
208	Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2010, 162, 331-340.	1.9	87
209	Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease. <i>New England Journal of Medicine</i> , 2010, 362, 1846-1848.	13.9	233
210	Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values. <i>European Journal of Endocrinology</i> , 2010, 162, 11-18.	1.9	112
211	Cortisol Production Rate Is Similarly Elevated in Obese Women with or without the Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3318-3324.	1.8	20
212	Increased Prevalence of Psychopathology and Maladaptive Personality Traits after Long-Term Cure of Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E129-E141.	1.8	121
213	Increased Psychopathology and Maladaptive Personality Traits, But Normal Cognitive Functioning, in Patients after Long-Term Cure of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E392-E402.	1.8	63
214	Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3758-3762.	1.8	100
215	Thyrotropin Secretion in Mild and Severe Primary Hypothyroidism Is Distinguished by Amplified Burst Mass and Basal Secretion with Increased Spikiness and Approximate Entropy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 928-934.	1.8	37
216	Association of the M1V<i>PRKAR1A</i> Mutation with Primary Pigmented Nodular Adrenocortical Disease in Two Large Families. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 338-342.	1.8	34

#	ARTICLE	IF	CITATIONS
217	Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 43-51.	1.8	198
218	Acromegaly Is Associated with an Increased Prevalence of Colonic Diverticula: A Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2073-2079.	1.8	46
219	Subtle Cognitive Impairments in Patients with Long-Term Cure of Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2699-2714.	1.8	140
220	Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. <i>Growth Hormone and IGF Research</i> , 2010, 20, 226-233.	0.5	54
221	Body Surface Area Determines the Cortisol Production Rate in Obese Patients with Polycystic Ovary Syndrome and Obese Healthy Women.. , 2010, , P2-404-P2-404.		0
222	Trauma Severity, but Not Hypopituitarism, Affects Cognitive Function after Traumatic Brain Injury: A Multi-Center Study in the Netherlands.. , 2010, , P1-260-P1-260.		0
223	Update in prolactinomas. <i>Netherlands Journal of Medicine</i> , 2010, 68, 104-12.	0.6	36
224	Lanreotide Autogel [®] in the Treatment of Acromegaly. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2150.	0.1	0
225	Cost-effectiveness of lanreotide Autogel [®] in treatment algorithms of acromegaly. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 223-234.	0.7	27
226	Endothelial Dysfunction in Diabetic Patients with Abnormal Myocardial Perfusion in the Absence of Epicardial Obstructive Coronary Artery Disease. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1980-1986.	2.8	16
227	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2009, 161, 923-931.	1.9	223
228	The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4671-4678.	1.8	33
229	Differences in Atherosclerotic Plaque Burden and Morphology Between Type 1 and 2 Diabetes as Assessed by Multislice Computed Tomography. <i>Diabetes Care</i> , 2009, 32, 1507-1512.	4.3	43
230	Diminished and irregular TSH secretion with delayed acrophase in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2009, 161, 695-703.	1.9	33
231	Pretreatment Insulin-Like Growth Factor-I Concentrations Predict Radiographic Osteoarthritis in Acromegalic Patients with Long-Term Cured Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2374-2379.	1.8	32
232	Thyrotropin Secretion Profiles Are Not Different in Men and Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3964-3967.	1.8	50
233	Disordered and Increased Adrenocorticotropin Secretion with Diminished Adrenocorticotropin Potency in Obese in Premenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2991-2997.	1.8	14
234	Impact of the Exon 3-Deleted Growth Hormone (GH) Receptor Polymorphism on Baseline Height and the Growth Response to Recombinant Human GH Therapy in GH-Deficient (GHD) and Non-GHD Children with Short Stature: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3721-3730.	1.8	90

#	ARTICLE	IF	CITATIONS
235	Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms. <i>European Journal of Endocrinology</i> , 2009, 160, 631-638.	1.9	23
236	Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1118-1124.	1.8	109
237	High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case-control study. <i>European Journal of Endocrinology</i> , 2009, 160, 357-365.	1.9	70
238	Usefulness of Carotid Intima-Media Thickness in Patients With Diabetes Mellitus as a Predictor of Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2009, 104, 1041-1046.	0.7	27
239	Pituitary-hormone secretion by thyrotropinomas. <i>Pituitary</i> , 2009, 12, 200-210.	1.6	14
240	Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. <i>Pituitary</i> , 2009, 12, 339-346.	1.6	39
241	Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. <i>European Journal of Internal Medicine</i> , 2009, 20, 387-393.	1.0	25
242	ACTH-producing pheochromocytoma: Clinical considerations and concise review of the literature. <i>European Journal of Internal Medicine</i> , 2009, 20, 682-685.	1.0	46
243	Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. <i>Diabetologia</i> , 2008, 51, 1581-1593.	2.9	60
244	Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. <i>Clinical Endocrinology</i> , 2008, 68, 605-609.	1.2	27
245	Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. <i>Clinical Endocrinology</i> , 2008, 69, 123-128.	1.2	65
246	Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls. <i>Clinical Endocrinology</i> , 2008, 69, 769-774.	1.2	33
247	Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. <i>Clinical Endocrinology</i> , 2008, 69, 775-784.	1.2	148
248	Somatostatin analog treatment is associated with an increased sleep latency in patients with long-term biochemical remission of acromegaly. <i>Growth Hormone and IGF Research</i> , 2008, 18, 446-453.	0.5	10
249	The role of pegvisomant in the treatment of acromegaly. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 691-704.	1.4	9
250	Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. <i>European Journal of Endocrinology</i> , 2008, 159, 363-367.	1.9	71
251	Rituximab in relapsing Graves' disease, a phase II study. <i>European Journal of Endocrinology</i> , 2008, 159, 609-615.	1.9	86
252	Mortality in Acromegaly: A Metaanalysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 61-67.	1.8	464

#	ARTICLE	IF	CITATIONS
253	Treatment and Follow-Up of Clinically Nonfunctioning Pituitary Macroadenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3717-3726.	1.8	216
254	Recombinant human GH replacement increases CD34+ cells and improves endothelial function in adults with GH deficiency. <i>European Journal of Endocrinology</i> , 2008, 159, 105-111.	1.9	17
255	Cardiac manifestations of GH deficiency after treatment for acromegaly: a comparison to patients with biochemical remission and controls. <i>European Journal of Endocrinology</i> , 2008, 159, 705-712.	1.9	10
256	Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease after 8 Years of Dopamine Agonist Therapy for Prolactinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3348-3356.	1.8	128
257	Influence of the d3-Growth Hormone (GH) Receptor Isoform on Short-Term and Long-Term Treatment Response to GH Replacement in GH-Deficient Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2828-2834.	1.8	49
258	Thyrotropin Secretion by Thyrotropinomas Is Characterized by Increased Pulse Frequency, Delayed Diurnal Rhythm, Enhanced Basal Secretion, Spikiness, and Disorderliness. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4052-4057.	1.8	29
259	Height Gain with Combined Growth Hormone and Gonadotropin-Releasing Hormone Analog Therapy in Two Pubertal Siblings with a Growth Hormone-Releasing Hormone Receptor Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 204-207.	1.8	6
260	Increased aortic root diameters in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2008, 159, 97-103.	1.9	33
261	Therapeutic options in the management of acromegaly: focus on lanreotide Autogel [®] . <i>Biologics: Targets and Therapy</i> , 2008, 2, 463.	3.0	16
262	The natural course of non-functioning pituitary macroadenomas. <i>European Journal of Endocrinology</i> , 2007, 156, 217-224.	1.9	175
263	Increased Daytime Somnolence despite Normal Sleep Patterns in Patients Treated for Nonfunctioning Pituitary Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3898-3903.	1.8	33
264	Bexarotene-Induced Hypothyroidism: Bexarotene Stimulates the Peripheral Metabolism of Thyroid Hormones. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2496-2499.	1.8	45
265	Associations of Serum Thyrotropin Concentrations with Recurrence and Death in Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2610-2615.	1.8	136
266	Growth hormone secretion and immunological function of a male patient with a homozygous STAT5b mutation. <i>European Journal of Endocrinology</i> , 2007, 156, 155-165.	1.9	27
267	Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism. <i>European Journal of Endocrinology</i> , 2007, 157, 709-716.	1.9	15
268	Mortality in Patients Treated for Cushing's Disease Is Increased, Compared with Patients Treated for Nonfunctioning Pituitary Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 976-981.	1.8	201
269	The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. <i>European Journal of Endocrinology</i> , 2007, 156, 455-462.	1.9	80
270	Quality of life is decreased in female patients treated for microprolactinoma. <i>European Journal of Endocrinology</i> , 2007, 157, 133-139.	1.9	48

#	ARTICLE	IF	CITATIONS
271	Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay. <i>Nuclear Medicine Communications</i> , 2007, 28, 123-127.	0.5	4
272	Attenuated pulse size, disorderly growth hormone and prolactin secretion with preserved nyctohemeral rhythm distinguish irradiated from surgically treated acromegaly patients. <i>Clinical Endocrinology</i> , 2007, 66, 070115055241003.	1.2	9
273	Progressive improvement of impaired visual acuity during the first year after transsphenoidal surgery for non-functioning pituitary macroadenoma. <i>Pituitary</i> , 2007, 10, 61-65.	1.6	53
274	Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. <i>Pituitary</i> , 2007, 10, 237-249.	1.6	50
275	Role of radiotherapy in the management of acromegaly. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 449-460.	1.2	10
276	Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. <i>Growth Hormone and IGF Research</i> , 2006, 16, 101-107.	0.5	42
277	Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. <i>Clinical Endocrinology</i> , 2006, 64, 284-291.	1.2	63
278	A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease. <i>Clinical Endocrinology</i> , 2006, 64, 060222010233007.	1.2	8
279	Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. <i>Clinical Endocrinology</i> , 2006, 64, 617-624.	1.2	57
280	Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. <i>Clinical Endocrinology</i> , 2006, 66, 061109020454001-???	1.2	83
281	Efficacy of needle-free administration of recombinant human growth hormone in adults with growth hormone deficiency. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 451-455.	1.1	9
282	Association of interferon- γ and interleukin 10 genotypes and serum levels with partial clinical remission in type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2006, 145, 480-484.	1.1	31
283	Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2006, 154, 525-531.	1.9	54
284	Quality of Life Is Decreased after Treatment for Nonfunctioning Pituitary Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3364-3369.	1.8	111
285	A Variable Degree of Intrauterine and Postnatal Growth Retardation in a Family with a Missense Mutation in the Insulin-Like Growth Factor I Receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3062-3070.	1.8	132
286	Clinical and Biochemical Characteristics of a Male Patient with a Novel Homozygous STAT5b Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3482-3485.	1.8	87
287	Observation Alone after Transsphenoidal Surgery for Nonfunctioning Pituitary Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1796-1801.	1.8	195
288	GH deficiency in patients irradiated for acromegaly: significance of GH stimulatory tests in relation to the 24 h GH secretion. <i>European Journal of Endocrinology</i> , 2006, 154, 851-858.	1.9	20

#	ARTICLE	IF	CITATIONS
289	Quality of life in treated adult craniopharyngioma patients. <i>European Journal of Endocrinology</i> , 2006, 154, 483-489.	1.9	103
290	Survival and Death Causes in Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 313-319.	1.8	248
291	Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. <i>European Journal of Endocrinology</i> , 2006, 155, 701-708.	1.9	43
292	Malignant prolactinoma: case report and review of the literature. <i>European Journal of Endocrinology</i> , 2006, 155, 523-534.	1.9	60
293	Nanomedicines in the treatment of acromegaly: focus on pegvisomant. <i>International Journal of Nanomedicine</i> , 2006, 1, 385-398.	3.3	21
294	High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. <i>Clinical Endocrinology</i> , 2005, 62, 197-204.	1.2	182
295	Growth hormone secretion in primary adrenal Cushing's syndrome is disorderly and inversely correlated with body mass index. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E63-E70.	1.8	9
296	Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. <i>European Journal of Endocrinology</i> , 2005, 152, 53-60.	1.9	23
297	Irregular and Frequent Cortisol Secretory Episodes with Preserved Diurnal Rhythmicity in Primary Adrenal Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1570-1577.	1.8	28
298	Effects of Dehydroepiandrosterone, Superimposed on Growth Hormone Substitution, on Quality of Life and Insulin-Like Growth Factor I in Patients with Secondary Adrenal Insufficiency: A Randomized, Placebo-Controlled, Cross-Over Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3295-3303.	1.8	61
299	Homozygous and Heterozygous Expression of a Novel Insulin-Like Growth Factor-I Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2855-2864.	1.8	285
300	Reversible Diastolic Dysfunction after Long-Term Exogenous Subclinical Hyperthyroidism: A Randomized, Placebo-Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6041-6047.	1.8	96
301	Morbidity after Long-Term Remission for Acromegaly: Persisting Joint-Related Complaints Cause Reduced Quality of Life. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2731-2739.	1.8	182
302	Treatment strategies for acromegaly. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 875-890.	1.0	12
303	Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. <i>European Journal of Endocrinology</i> , 2005, 153, 231-238.	1.9	24
304	Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. <i>Growth Hormone and IGF Research</i> , 2005, 15, 200-206.	0.5	32
305	Pharmacologic Therapies for Acromegaly. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2005, 4, 43-53.	1.8	24
306	Quality of Life in Patients after Long-Term Biochemical Cure of Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3279-3286.	1.8	225

#	ARTICLE	IF	CITATIONS
307	Current pharmacotherapy for acromegaly: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2393-2405.	0.9	24
308	Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E25-E30.	1.8	41
309	Determinants of Survival in Treated Acromegaly in a Single Center: Predictive Value of Serial Insulin-Like Growth Factor I Measurements. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2789-2796.	1.8	188
310	Pituitary Magnetic Resonance Imaging Is Not Required in the Postoperative Follow-Up of Acromegalic Patients with Long-Term Biochemical Cure after Transsphenoidal Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4320-4324.	1.8	27
311	Decreased Quality of Life in Patients with Acromegaly Despite Long-Term Cure of Growth Hormone Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5369-5376.	1.8	213
312	Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. <i>European Journal of Endocrinology</i> , 2004, 150, 489-495.	1.9	65
313	Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. <i>Clinical Endocrinology</i> , 2004, 60, 568-575.	1.2	49
314	Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease. <i>Clinical Endocrinology</i> , 2004, 60, 765-772.	1.2	26
315	Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. <i>Clinical Endocrinology</i> , 2004, 61, 61-74.	1.2	165
316	Increased Prevalence of Regurgitant Valvular Heart Disease in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 71-75.	1.8	138
317	Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. <i>Clinical Endocrinology</i> , 2003, 58, 288-295.	1.2	42
318	Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. <i>Clinical Endocrinology</i> , 2003, 58, 428-435.	1.2	120
319	Outcome of Palliative Embolization of Bone Metastases in Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3184-3189.	1.8	106
320	Long-Term Predictive Value of Postsurgical Cortisol Concentrations for Cure and Risk of Recurrence in Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5858-5864.	1.8	161
321	Aminophylline stimulates insulin secretion in patients with type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2001, 50, 1030-1035.	1.5	14
322	Indomethacin Does Not Affect Endogenous Glucose Production in Type 2 Diabetes Mellitus. <i>Hormone and Metabolic Research</i> , 2001, 33, 659-663.	0.7	2
323	The Quantification of Gluconeogenesis in Healthy Men by 2H ₂ O and [2-13C]Glycerol Yields Different Results: Rates of Gluconeogenesis in Healthy Men Measured with 2H ₂ O Are Higher Than Those Measured with [2-13C]Glycerol. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2220-2226.	1.8	76
324	The Effects of Carbohydrate Variation in Isocaloric Diets on Glycogenolysis and Gluconeogenesis in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1963-1967.	1.8	44

#	ARTICLE	IF	CITATIONS
325	No Correlation between A(→1438)G Polymorphism in 5-HT2A Receptor Gene Promoter and the Density of Frontal Cortical 5-HT2A Receptors in Schizophrenia. Human Heredity, 1999, 49, 103-105.	0.4	63
326	5-HT2A receptor polymorphism and steady state receptor expression in schizophrenia. Lancet, The, 1997, 349, 1815.	6.3	40
327	Awareness & participation in rare disease registries within the European reference network on rare endocrine conditions (Endo-ERN). Endocrine Abstracts, 0, , .	0.0	0
328	Loss of glucocorticoid rhythm induces an osteoporotic phenotype in mice. Endocrine Abstracts, 0, , .	0.0	0
329	Opioids and their endocrine effects: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	0
330	Opioids and their endocrine effects: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	0
331	Costs and Its Determinants in Pituitary Tumour Surgery. Frontiers in Endocrinology, 0, 13, .	1.5	1